Gender-based violence screening methods preferred by women visiting a public hospital in Pune, India

Citation: Suryavanshi N, Naik S, Waghmare S, Gupte N, Khan S, Mave V, Deluca A, Gupta A, Golub J, Bollinger RC, Shankar A. Gender-based violence screening methods preferred by women visiting a public hospital in Pune, India. BMC Womens Health. 2018 Jan 15;18(1):19. doi: 10.1186/s12905-018-0515-2. PMID: 29334936. PMCID: PMC5769341.

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/29334936

Summary: 
Background: Gender-based violence (GBV) is a major global public health concern and is a risk factor for adverse health outcomes. Early identification of GBV is crucial for improved health outcomes. Interactions with health care providers may provide a unique opportunity for routine GBV screening, if a safe, confidential environment can be established.

Methods: Between November 2014 and February 2015, a cross-sectional, observational study was conducted where women were interviewed about their opinions concerning GBV screening in a tertiary health care setting in Pune, India. Trained counsellors interviewed 300 women at different out-patient and in-patient departments using a semi-structured questionnaire.

Results: Twenty-three percent of these women reported experiencing GBV in their life. However, 90% of women said they had never been asked about GBV in a health care setting. Seventy-two percent expressed willingness to be asked about GBV by their health care providers, with the preferred provider being nurses or counsellors. More than half (53%) women reported face-to-face interview as the most preferred method for screening. There were no major differences in these preferences by GBV history status.

Conclusions: Our study provides evidence for preferred GBV screening methods and optimal provider engagement as perceived by women attending a public hospital.

BMC Womens Health. 2018;18(1): e19

Categories

CRS
Topics

Clinical Trials

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More